TRASTUZUMAB (Herceptin) prior authorization at UPMC Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UPMC Health Plan requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
UPMC Health Plan reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UPMC Health Plan's medical policy URL referenced in the cover letter
UPMC Health Plan's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Highmark-vs-UPMC network access disputes (historical PA consent decree)
- Specialty drug PA
- Behavioral health prior auth
- Out-of-network reductions
TRASTUZUMAB (Herceptin)-specific denial patterns and context
Across payers (not just UPMC Health Plan), TRASTUZUMAB (Herceptin)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when an UPMC Health Plan denial sticks and the patient needs bridge access while appealing.
How UPMC Health Plan approaches Biosimilars PAs
UPMC Health Plan's Biosimilars reviewer typically anchors TRASTUZUMAB (ONTRUZANT) prior-auth decisions on specialty drug pa. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at UPMC Health Plan is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. UPMC Health Plan treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. UPMC Health Plan is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Integrated payer-provider arm of UPMC (~4M members).
If the PA is denied
UPMC Health Plan gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.upmchealthplan.com/providers) with the same packet plus a peer-reviewed citation supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact UPMC Health Plan
- Provider portal: https://www.upmchealthplan.com/providers
Frequently asked questions
What documentation does UPMC Health Plan need for TRASTUZUMAB (Herceptin) prior auth?
UPMC Health Plan's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UPMC Health Plan?
Standard TRASTUZUMAB (Herceptin) PA decisions at UPMC Health Plan: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does UPMC Health Plan most often reject TRASTUZUMAB (Herceptin) for?
Across UPMC Health Plan's book the common rejection patterns include: Highmark-vs-UPMC network access disputes (historical PA consent decree); Specialty drug PA; Behavioral health prior auth. For TRASTUZUMAB (Herceptin) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Can UPMC Health Plan force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
UPMC Health Plan can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). External-review escalation for UPMC Health Plan fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with UPMC Health Plan on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to UPMC Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com